Research Topics
Genomes and Genes | Mary B DalySummaryAffiliation: Fox Chase Cancer Center Country: USA Publications
Research Grants
| Collaborators
|
Detail Information
Publications
Common breast cancer susceptibility alleles are associated with tumour subtypes in BRCA1 and BRCA2 mutation carriers: results from the Consortium of Investigators of Modifiers of BRCA1/2Anna Marie Mulligan
Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, University of Cambridge, 2 Worts Causeway, Cambridge, CB1 8RN, UK
Breast Cancer Res 13:R110. 2011..It is currently unknown how these alleles are associated with different breast cancer subtypes in BRCA1 and BRCA2 mutation carriers defined by estrogen (ER) or progesterone receptor (PR) status of the tumour...- Rare variants in the ATM gene and risk of breast cancerDavid E Goldgar
Department of Dermatology, University of Utah School of Medicine, 30 N 1900 E, Salt Lake City, UT 84132 2101, USA
Breast Cancer Res 13:R73. 2011..However, the magnitude of risk and the subset of variants that are pathogenic for breast cancer remain unresolved... - Exploring the link between MORF4L1 and risk of breast cancerGriselda Martrat
Translational Research Laboratory, Catalan Institute of Oncology, Bellvitge Institute for Biomedical Research IDIBELL, Gran Via 199, L Hospitalet del Llobregat 08908, Spain
Breast Cancer Res 13:R40. 2011..To gain deeper insight into this pathway and its influence on cancer risk, we searched for novel components through protein physical interaction screens... - Contribution of large genomic BRCA1 alterations to early-onset breast cancer selected for family history and tumour morphology: a report from The Breast Cancer Family RegistryLetitia D Smith
Genetic Epidemiology Laboratory, Department of Pathology, University of Melbourne, Melbourne, Victoria 3010, Australia
Breast Cancer Res 13:R14. 2011..We sought to test the value of selecting women for BRCA1 mutation testing on the basis of family history and/or breast tumour morphology criteria as well as the value of testing for large genomic alterations in BRCA1... - Genetic variation in insulin-like growth factor signaling genes and breast cancer risk among BRCA1 and BRCA2 carriersSusan L Neuhausen
Department of Epidemiology, University of California Irvine, 224 Irvine Hall, Irvine, CA 92697, USA
Breast Cancer Res 11:R76. 2009..In this study, we investigate the association of variants in genes involved in IGF signaling and risk of breast cancer in women who carry deleterious BRCA1 and BRCA2 mutations... - The impact of social roles on the experience of men in BRCA1/2 families: implications for counselingMary B Daly
Division of Population Science, Fox Chase Cancer Center, 333 Cottman Avenue, Philadelphia, PA 19111, USA
J Genet Couns 18:42-8. 2009..Genetic counselors are in a position to inform at-risk males of their genetic risk, and to help them explore their personal health options... 
How to establish a high-risk cancer genetics clinic: limitations and successesMary B Daly
Fox Chase Cancer Center, 333 Cottman Avenue, Philadelphia, PA 19111 2497, USA
Curr Oncol Rep 7:469-74. 2005..The societal benefits include a more educated public armed with the information needed to make health decisions appropriate for the individual level of risk...- Occult ovarian cancers identified at risk-reducing salpingo-oophorectomy in a prospective cohort of BRCA1/2 mutation carriersSusan M Domchek
Abramson Cancer Center, The University of Pennsylvania School of Medicine, 3W Perelman Center, 3400 Civic Center Boulevard, Philadelphia, PA 19104, USA
Breast Cancer Res Treat 124:195-203. 2010..An unacceptably high proportion of pathologic examinations did not adequately examine ovaries and fallopian tubes obtained at RRSO... - Association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortalitySusan M Domchek
Abramson Cancer Center and Department of Medicine, University of Pennsylvania School of Medicine, Philadelphia, USA
JAMA 304:967-75. 2010..Mastectomy and salpingo-oophorectomy are widely used by carriers of BRCA1 or BRCA2 mutations to reduce their risks of breast and ovarian cancer... 
Bilateral prophylactic oophorectomy and bilateral prophylactic mastectomy in a prospective cohort of unaffected BRCA1 and BRCA2 mutation carriersTara M Friebel
Center for Clinical Epidemiology and Biostatistics, University of Pennsylvania School of Medicine, Philadelphia, PA 19104 6021, USA
Clin Breast Cancer 7:875-82. 2007..The availability of these risk-reduction strategies is an important consideration in the decision to undergo genetic testing...- Breast and ovarian cancer risk and risk reduction in Jewish BRCA1/2 mutation carriersBrian S Finkelman
Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104 6021, USA
J Clin Oncol 30:1321-8. 2012..Three mutations in these genes (185delAG, 5382insC, and 6174delT) occur at high frequency in Ashkenazi Jews. We evaluated how these common Jewish mutations (CJMs) affect cancer risks and risk reduction... - Mortality after bilateral salpingo-oophorectomy in BRCA1 and BRCA2 mutation carriers: a prospective cohort studySusan M Domchek
Abramson Cancer Centre, Department of Medicine, University of Pennsylvania School of Medicine, Philadelphia, PA 19104-6021, USA
Lancet Oncol 7:223-9. 2006..Together, these data could give information to women who are considering genetic testing... - Allelic imbalance in BRCA1 and BRCA2 gene expression is associated with an increased breast cancer riskXiaowei Chen
Medical Science Division, Fox Chase Cancer Center, Philadelphia, PA 19111 2497, USA
Hum Mol Genet 17:1336-48. 2008..02 and P < 0.02, respectively). In conclusion, we have found that AI affecting BRCA1 and to a lesser extent BRCA2 may contribute to both familial and non-familial forms of breast cancer... - Effect of short-term hormone replacement therapy on breast cancer risk reduction after bilateral prophylactic oophorectomy in BRCA1 and BRCA2 mutation carriers: the PROSE Study GroupTimothy R Rebbeck
Center for Clinical Epidemiology and Biostatistics, The University of Pennsylvania School of Medicine, Philadelphia, 19104, USA
J Clin Oncol 23:7804-10. 2005..Thus, we evaluated whether the breast cancer risk reduction conferred by BPO in BRCA1/2 mutation carriers is altered by use of post-BPO HRT... - Intention to communicate BRCA1/BRCA2 genetic test results to the familyAndrea M Barsevick
Fox Chase Cancer Center, Philadelphia, PA 19111 2497, USA
J Fam Psychol 22:303-12. 2008..These results extend the theory of planned behavior by showing that gender and generation influence intention when the relative's opinion is unknown... - Modification of BRCA1-Associated Breast and Ovarian Cancer Risk by BRCA1-Interacting GenesTimothy R Rebbeck
Abramson Cancer Center, Center for Clinical Epidemiology and Biostatistics, and Department of Medicine, The University of Pennsylvania Perleman School of Medicine, Philadelphia, Pennsylvania, USA
Cancer Res 71:5792-805. 2011..Overall, the data suggest that genomic variation at multiple loci that encode proteins that interact biologically with BRCA1 are associated with modified breast cancer and ovarian cancer risk in women who carry BRCA1 mutations... - The joint effect of smoking and AIB1 on breast cancer risk in BRCA1 mutation carriersSusan Colilla
Department of Biostatistics and Epidemiology and Medicine and Genetics, University of Pennsylvania School of Medicine, Philadelphia, PA 19104, USA
Carcinogenesis 27:599-605. 2006.... - Dietary intake and breast density in high-risk women: a cross-sectional studyMarilyn Tseng
Division of Population Science, Fox Chase Cancer Center, 333 Cottman Avenue, Philadelphia, PA 19111, USA
Breast Cancer Res 9:R72. 2007..The objective of the present study was to determine whether diet, a modifiable risk factor, is related to breast density among women at high genetic risk for breast cancer... - Age-dependent morphological alterations of human ovaries from populations with and without BRCA mutationsKathy Qi Cai
Ovarian Cancer Program and Department of Medical Oncology, Fox Chase Cancer Center, Philadelphia, PA 19111, USA
Gynecol Oncol 103:719-28. 2006.... - Enhanced counseling for women undergoing BRCA1/2 testing: impact on subsequent decision making about risk reduction behaviorsSuzanne M Miller
Fox Chase Cancer Center, Philadelphia, Pennsylvania, PA 19111, USA
Health Educ Behav 32:654-67. 2005..The results indicate that the use of enhanced counseling can play an important role in decision making about risk reduction behaviors following BRCA1/2 testing... - Focus on epithelial ovarian cancerRobert F Ozols
Fox Chase Cancer Center, Philadelphia, PA 19111, USA
Cancer Cell 5:19-24. 2004 - Genetic/familial high-risk assessment: breast and ovarianMary B Daly
Fox Chase Cancer Center, Philadelphia, PA, USA
J Natl Compr Canc Netw 4:156-76. 2006 - Modification of ovarian cancer risk by BRCA1/2-interacting genes in a multicenter cohort of BRCA1/2 mutation carriersTimothy R Rebbeck
Abramson Cancer Center, The University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania 19104 6021, USA
Cancer Res 69:5801-10. 2009..026). Variants in genes that interact biologically withBRCA1 and/or BRCA2 may be associated with modified ovarian cancer risk in women who carry BRCA1/2 mutations... - New strategies in ovarian cancer: uptake and experience of women at high risk of ovarian cancer who are considering risk-reducing salpingo-oophorectomySuzanne M Miller
Psychosocial and Biobehavioral Medicine Program, Fox Chase Cancer Center, Cheltenham, Pennsylvania 19012, USA
Clin Cancer Res 16:5094-106. 2010..These findings indicate that when designing decision aids, demographic, medical history, and psychosocial variables need to be addressed in order to facilitate quality decision making... - A prospective study of quality of life among women undergoing risk-reducing salpingo-oophorectomy versus gynecologic screening for ovarian cancerCarolyn Y Fang
Division of Population Science, Fox Chase Cancer Center, 333 Cottman Avenue, Philadelphia, PA 19111, USA
Gynecol Oncol 112:594-600. 2009..The primary objective of the study was to prospectively assess quality of life (QOL) among women at increased risk of ovarian cancer who are undergoing risk-reducing salpingo-oophorectomy (RRSO) or serial screening... - When parents disclose BRCA1/2 test results: their communication and perceptions of offspring responseAngela R Bradbury
Department of Clinical Genetics, Fox Chase Cancer Center, Philadelphia, Pennsylvania 19111 2497, USA
Cancer 118:3417-25. 2012..Little is known about the prevalence and predictors of parent communication to offspring and how offspring respond to this communication... - Bilateral prophylactic mastectomy reduces breast cancer risk in BRCA1 and BRCA2 mutation carriers: the PROSE Study GroupTimothy R Rebbeck
Center for Clinical Epidemiology and Biostatistics, Abramson Family Cancer Research Institute, The University of Pennsylvania, Philadelphia, PA 19104-6021, USA
J Clin Oncol 22:1055-62. 2004..CONCLUSION: Bilateral prophylactic mastectomy reduces the risk of breast cancer in women with BRCA1/2 mutations by approximately 90%... - Mentoring nurses in familial cancer risk assessment and counseling: lessons learned from a formative evaluationAgnes Masny
Fox Chase Cancer Center, Philadelphia, PA 19111, USA
J Genet Couns 17:196-207. 2008.... - Cancer genetic risk assessment and referral patterns in primary careHetal S Vig
Fox Chase Cancer Center, Philadelphia, Pennsylvania, USA
Genet Test Mol Biomarkers 13:735-41. 2009..This study was undertaken to describe cancer risk assessment practices among primary care providers (PCPs)... - Psychosocial correlates of intention to undergo prophylactic oophorectomy among women with a family history of ovarian cancerCarolyn Y Fang
Fox Chase Cancer Center, Philadelphia, PA 19111, USA
Prev Med 37:424-31. 2003..The purpose of this study was to examine sociodemographic and psychosocial correlates of intention to undergo prophylactic oophorectomy among women with a family history of ovarian cancer... - Intronic alterations in BRCA1 and BRCA2: effect on mRNA splicing fidelity and expressionXiaowei Chen
Department of Medical Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania 19111, USA
Hum Mutat 27:427-35. 2006..Our studies help to clarify the aberrant splicing in BRCA1 and BRCA2 as well as provide information that can be used clinically to help counsel breast/ovarian cancer prone families... - Correlates of soy food consumption in women at increased risk for breast cancerCarolyn Y Fang
Division of Population Science, Fox Chase Cancer Center, Cheltenham, PA 19012, USA
J Am Diet Assoc 105:1552-8. 2005.... - Knowledge and perceptions of familial and genetic risks for breast cancer risk in adolescent girlsAngela R Bradbury
Division of Hematology Oncology, Department of Medicine, University of Pennsylvania, 3 West Perelman Center 3400 Civic Center Boulevard, Philadelphia, PA 19104, USA
Breast Cancer Res Treat 136:749-57. 2012..Research evaluating the impact of awareness and perceptions of breast cancer risk on psychosocial, health, and risk behaviors is needed to develop strategies to optimize responses to cancer risk... - Coping with ovarian cancer risk: the moderating effects of perceived control on coping and adjustmentCarolyn Y Fang
Division of Population Science, Fox Chase Cancer Center, Philadelphia, PA 19012, USA
Br J Health Psychol 11:561-80. 2006..The present study was a longitudinal study of the effects of perceived control and problem-focused coping on changes in psychological adjustment and behavioural outcomes among women at increased risk for ovarian cancer... - Food frequency questionnaires and overnight urines are valid indicators of daidzein and genistein intake in U.S. women relative to multiple 24-h urine samplesMarilyn Tseng
Division of Population Science, Fox Chase Cancer Center, Philadelphia, Pennsylvania 19130, USA
Nutr Cancer 60:619-26. 2008..We conclude that targeted soy food questionnaires, comprehensive FFQs, and multiple overnight urines are all reasonable options for assessing isoflavone intake in epidemiologic studies... - The search for predictive patterns in ovarian cancer: proteomics meets bioinformaticsMary B Daly
Division of Population Science, Fox Chase Cancer Center, 7701 Burholme Avenue, Philadelphia, PA 19111, USA
Cancer Cell 1:111-2. 2002..Proteomic patterns in serum that discriminate between malignant and benign ovaries may provide a powerful tool for screening in high risk women... - Acculturation and breast density in foreign-born, U.S. Chinese womenMarilyn Tseng
Division of Population Science, Fox Chase Cancer Center, Philadelphia, PA 19111, USA
Cancer Epidemiol Biomarkers Prev 15:1301-5. 2006..Future longitudinal research will examine whether the association is due to early-life factors, postmigration lifestyle changes, or perimenopausal exposures... - Identifying breast cancer risk loci by global differential allele-specific expression (DASE) analysis in mammary epithelial transcriptomeChuan Gao
Cancer Epigenetics Program, Fox Chase Cancer Center, Philadelphia, PA 19111, USA
BMC Genomics 13:570. 2012.... - Communication of BRCA1 and BRCA2 results to at-risk relatives: a cancer risk assessment program's experienceJosephine Wagner Costalas
Population Science Division, Family Risk Assessment Program, Fox Chase Cancer Center, Philadelphia, PA 19111, USA
Am J Med Genet C Semin Med Genet 119:11-8. 2003..001). Individuals are disclosing their test results to their relatives. Probands who are BRCA1- or BRCA2-positive are more likely to experience difficulty and distress with the communication of their test results to family members... - Loss of surface and cyst epithelial basement membranes and preneoplastic morphologic changes in prophylactic oophorectomiesIsabelle H Roland
Ovarian Cancer Program, Fox Chase Cancer Center, Philadelphia, Pennsylvania 19111, USA
Cancer 98:2607-23. 2003..The authors speculated that the purging of the basement membrane may be similar to the proteolysis during gonadotropin-stimulated ovulation, a cyclooxygenase 2 (Cox-2)-mediated process... - A mechanism for cox-2 inhibitor anti-inflammatory activity in chemoprevention of epithelial cancersElizabeth R Smith
Ovarian Cancer Program, Department of Medical Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania, USA
Cancer Epidemiol Biomarkers Prev 13:144-5. 2004 - Tamoxifen in ductal carcinoma in situMary B Daly
Department of Population Science, Fox Chase Cancer Center, Philadelphia, PA 19111, USA
Semin Oncol 33:647-9. 2006..Tamoxifen should be considered as an adjunct to treatment for women undergoing breast-conserving surgery for ER-positive DCIS... - Risk-reducing salpingo-oophorectomy for the prevention of BRCA1- and BRCA2-associated breast and gynecologic cancer: a multicenter, prospective studyNoah D Kauff
Clinical Genetics and Gynecology Services, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, Box 192, New York, NY 10021, USA
J Clin Oncol 26:1331-7. 2008.... - The AIB1 polyglutamine repeat does not modify breast cancer risk in BRCA1 and BRCA2 mutation carriersAmanda B Spurdle
The Queensland Institute of Medical Research, Brisbane, Australia
Cancer Epidemiol Biomarkers Prev 15:76-9. 2006..Given the large sample size, with more than adequate power to detect previously reported effects, we conclude that the AIB1 glutamine repeat does not substantially modify risk of breast cancer in BRCA1 and BRCA2 mutation carriers... - Breast cancer screening and diagnosisTherese B Bevers
University of Texas, M. D. Anderson Cancer Center, Houston, TX 77030, USA
J Natl Compr Canc Netw 4:480-508. 2006 - The Breast Cancer Family Registry: an infrastructure for cooperative multinational, interdisciplinary and translational studies of the genetic epidemiology of breast cancerEsther M John
Clinical and Genetic Epidemiology Research Branch, Division of Cancer Control and Population Sciences, National Cancer Institute, Bethesda, Maryland, USA
Breast Cancer Res 6:R375-89. 2004.... - Tailoring breast cancer treatment to genetic status: the challenges aheadMary B Daly
J Clin Oncol 22:1776-7. 2004 - Determinants of preferences for genetic counselling in Jewish womenCarmel Apicella
Centre for Molecular, Environmental, Genetic and Analytic Epidemiology, University of Melbourne, Melbourne, Australia
Fam Cancer 5:159-67. 2006..Understanding preferences and their predictors may assist cancer genetic services to provide clients with greater benefits from counselling... - No increased risk of breast cancer associated with alcohol consumption among carriers of BRCA1 and BRCA2 mutations ages <50 yearsValerie McGuire
Department of Health Research and Policy, Stanford University School of Medicine, Health Research and Stanford, CA 94305-5405, USA
Cancer Epidemiol Biomarkers Prev 15:1565-7. 2006 - Common breast cancer-predisposition alleles are associated with breast cancer risk in BRCA1 and BRCA2 mutation carriersAntonis C Antoniou
Cancer Research UK, Genetic Epidemiology Unit, Department of Public Health and Primary Care, University of Cambridge, UK
Am J Hum Genet 82:937-48. 2008.... - Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutationsTimothy R Rebbeck
Center for Clinical Epidemiology and Biostatistics, University of Pennsylvania School of Medicine, Philadelphia 19104 6021, USA
N Engl J Med 346:1616-22. 2002..We investigated whether this procedure reduces the risk of cancers of the coelomic epithelium and breast in women who carry such mutations... - Genetic and functional analysis of CHEK2 (CHK2) variants in multiethnic cohortsDaphne W Bell
Massachusetts General Hospital Cancer Center, Charlestown, MA, USA
Int J Cancer 121:2661-7. 2007.... - AURKA F31I polymorphism and breast cancer risk in BRCA1 and BRCA2 mutation carriers: a consortium of investigators of modifiers of BRCA1/2 studyFergus J Couch
Department of Laboratory Medicine and Pathology, Mayo Clinic College of Medicine, 200 First Street Southwest, Rochester, MN 55905, USA
Cancer Epidemiol Biomarkers Prev 16:1416-21. 2007..In summary, the F31I polymorphism in AURKA is not associated with a modified risk of breast cancer in BRCA1 and BRCA2 carriers... - Genetic linkage of prostate cancer risk to the chromosome 3 region bearing FHITGarry P Larson
Division of Molecular Medicine, Beckman Research Institute, City of Hope National Medical Center, 1500 East Duarte Road, Duarte, CA 91010 3000, USA
Cancer Res 65:805-14. 2005..54, df = 1, P = 0.0035). Our results strongly suggest involvement of germline variations of FHIT in prostate cancer risk... - Evaluation of linkage of breast cancer to the putative BRCA3 locus on chromosome 13q21 in 128 multiple case families from the Breast Cancer Linkage ConsortiumDeborah Thompson
CRC Genetic Epidemiology Unit, Strangeways Research Laboratories, University of Cambridge, Cambridge CB1 4RN, United Kingdom
Proc Natl Acad Sci U S A 99:827-31. 2002..65 was -11.0]. We conclude that, if a susceptibility gene does exist at this locus, it can only account for a small proportion of non-BRCA1/2 families with multiple cases of early-onset breast cancer... - Breast cancer risk reductionTherese B Bevers
National Comprehensive Cancer Network
J Natl Compr Canc Netw 5:676-701. 2007 - Prospective multicenter trial to determine the feasibility of collection and predictive ability of breast fluid analysis in postmenopausal women receiving SERMsEdward R Sauter
Department of Surgery, University of Missouri Columbia, One Hospital Drive, Rm N510, Columbia, MO 65212, USA
Breast 16:489-94. 2007..Multiinstitutional clinical trials in postmenopausal women using NAF biomarkers as the primary endpoints are feasible... - BRCA2 mutation-associated breast cancers exhibit a distinguishing phenotype based on morphology and molecular profiles from tissue microarraysAnita L Bane
Department of Pathology, Samuel Lunenfeld Research Institute, Mount Sinai Hospital, University of Toronto, 600 University Avenue, Toronto, Ontario, Canada
Am J Surg Pathol 31:121-8. 2007.... - Specific keynote: chemoprevention of ovarian cancer: the journey beginsRobert F Ozols
Fox Chase Cancer Center
Gynecol Oncol 88:S59-66; discussion S67-70. 2003 - Symptoms of ovarian cancer--where to set the bar?Mary B Daly
JAMA 291:2755-6. 2004
Research Grants
- COMMUNICATING GENETIC TEST RESULTS TO THE FAMILYMary Daly; Fiscal Year: 2007..Our long-term goal is both to advance the field of cancer communication science and to create a bridge to the development of practice guidelines and the diffusion of best practice to the genetic counseling community. ..
- Benign Breast Disease: A New Frontier for PreventionMary Daly; Fiscal Year: 2007..The award will also facilitate my efforts to formalize a novel clinical genetics training rotation within the medical oncology fellowship, and will afford more opportunities to mentor students at all levels of training. ..
- ADVANCED CANCER RISK COUNSELING TRAINING FOR NURSESMary Daly; Fiscal Year: 2006..Course and mentoring evaluations will assess if this continuing education format is an effective method for preparing nurses skilled in the delivery of cancer genetic risk assessment and management. ..
- Benign Breast Registry to Assess Valid EndpointsMary Daly; Fiscal Year: 2005..If promising, this work would lead to a larger prospective clinical research project to validate the findings of the pilot study and explore mechanisms of action. ..
- COMMUNICATING GENETIC TEST RESULTS TO THE FAMILYMary Daly; Fiscal Year: 2002..If effective, this protocol will provide a model for risk communication within families facing genetic risk for a wide range of diseases. ..